

Table 1. Summary Characteristics of Included Studies

Characteristics	No of studies (No of patients)
Eligible studies:	
Total No of studies (No of patients)	81 (45935)
RCTs for COVID-19	10 (7898)
Observational studies for COVID-19	59 (26735)
Observational studies for SARS	12 (11302)
Median (IQR) %, mortality	
COVID-19	17 (11.7-24)
SARS	6.3 (4.6-12.6)
Median (IQR) %, male	
COVID-19	57.4 (50.2-64.6)
SARS	46 (42.2-49.7)
Median (IQR), age (years)	
COVID-19	61 (55-66)
SARS	37 (35-39)
Median (IQR) follow-up (days)	
COVID-19	28 (24-30)
SARS	45 (28-90)
Country:	
COVID-19	
European	18 (15750)
American	6 (2872)
Asian-pacific	43 (15105)
Multinational	2 (910)
SARS	
Asian-pacific	11 (9369)
Multinational	1 (1935)
Administration of glucocorticoids:	
Types	
COVID-19	
Dexamethasone	3 (2298)
Hydrocortisone	3 (474)
Methylprednisolone	19 (1612)
Multiple types	9 (3058)
Not available	35 (5031)
SARS	
Hydrocortisone	1 (621)
Methylprednisolone	3 (746)
Multiple types	3 (1498)
Not available	5 (1493)
Median (IQR), doses (equivalent methylprednisolone, mg/day)	
COVID-19	61 (47-80)
SARS	97 (80-120)

Abbreviations: IQR, interquartile range; RCTs, randomized controlled trials; COVID-19, coronavirus disease 2019; SARS, severe acute respiratory syndrome.